Collegium Pharma (COLL): Management Changes A Positive - Needham
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil prices, producer inflation ease
- Oil pares losses after reports Houthis attacked Saudi Aramco refinery
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Collegium Pharma (COLL) Secures Additional Managed Care Coverage for Xtampza ER for Medicare Part D Patients
June 1, 2017 7:13 AM EDTCollegium Pharmaceutical, Inc. (NASDAQ: COLL) today announced that one of the largest managed care organizations with approximately 8 million Medicare Part D lives has added Xtampza® ER to its Medicare Part D formularies. Effective June 1, 2017, Xtampza ER is the exclusive oxycodone extended-release product for this... More
